**Supplemental Methods**

The following antibodies were used: anti-human C5 (eculizumab, Alexion), mouse anti-human CD46-APC (ThermoFisher, #A15711, 1:50), mouse anti-human CD55-APC (BioLegend, #311312, 1:50), mouse anti-human CD59-APC (Life Technologies, #17-0596-42, 1:50), mouse anti-human CD35-AF647 (BD, #565329, 1:50), mouse anti-human CD11b-APC (Invitrogen, #17-0118-42, 1:50), mouse anti-human CD11c-APC (BD, #333144, 1:50), mouse anti-human C3aR-APC (Biolegend, #345805, 1:50), mouse anti-human C5aR-APC (Biolegend, #344309, 1:50), mouse anti-human C3-biotin (LSBio, #LS-C62849, 1:25), biotinylated polyclonal goat anti-human C3 (MyBioSource, #MBS6003125, 1:2000) goat anti-human C4-biotin (MyBioSource, #MBS560216, 1:100), mouse anti-human C5b9-biotin (Bio-Techne, #NBP2-23494, 1:500), Streptavidin-APC (eBioscience, #17-4317-82, 1:100), Annexin V-PE (BD biosciences, #556422, 1:20), 7AAD (Pharmingen, #555816, 1:25), goat anti-human IgM µ-chain-biotin (Sigma Aldrich, #B1265, 1:300), or respective isotypes.

**Table e-1: MMN patient characteristics**

|  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- |
|   |   |   |   |   |  |  |
| Patient  | Gender | Age at onset | Age at diagnosis | Anti-GM1 titer | EFNS 2010 | IVIg treatment |
| MMN-005 | Male | 23 | 26 | 800 | Definitive | Yes |
| MMN-011 | Male | 33 | 34 | 800 | Definitive | Yes |
| MMN-012 | Male | 48 | 50 | 200 | Probable | Yes |
| MMN-014 | Male | 44 | 47 | 0 | Definitive | Yes |
| MMN-016 | Male | 41 | 46 | 50 | Definitive | Yes |
| MMN-017 | Male | 40 | 50 | 800 | Definitive | Yes |
| MMN-018 | Female | 48 | 50 | 50 | Definitive | Yes |
| MMN-022 | Male | 29 | 45 | 400 | Definitive | Yes |
| MMN-024 | Male | 36 | 52 | 6400 | Definitive | Yes |
| MMN-029 | Male  | 47 | 50 | 0 | Possible | Yes |
| MMN-031 | Female | 46 | 56 | 100 | Definitive  | Yes |
| MMN-032 | Male | 40 | 45 | 0 | Definitive | Yes |
| MMN-034 | Male | 30 | 32 | 0 | Probable | No |
| MMN-035 | Female | 42 | 44 | 100 | Probable | Yes |
| MMN-036 | Female | 49 | 50 | 400 | Definitive | N/A |
| MMN-039 | Female | 39 | 50 | 0 | Probable | Yes |
| MMN-042 | Male | 24 | 26 | 1600 | Probable | Yes |
| MMN-052 | Male | 66 | 69 | 25600 | Definitive | Yes |
| MMN-068 | Female | 51 | 66 | 1600 | Definitive | Yes |
| MMN-073 | Male | 23 | 36 | 25600 | Probable | Yes |

**Figure e-1: qPCR analysis of mCRPs and CRs on iPSC-derived MNs**



mRNA was isolated from cultured iPSC MNs and PBMCs from healthy volunteers using the Qiagen miRNeasy kit. cDNA synthesis was conducted using SuperScript IV Reverse Transcriptase and Random Hexamer Primers according to manufacturer’s instructions (ThermoFisher). qPCR analysis was conducted on a VIA7 using TaqMan Gene Expression Assay reagents. ActB was used as housekeeping gene, data were normalized and depicted as fold change (FC) to the expression of C3aR on PBMCs (set as one, \*). Expression of CD46, CD55, CD59, and C3aR was confirmed. Lower levels of C5aR mRNA were detected.